STAMFORD, Conn., Dec. 8 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. , a medical technology producer specializing in cancer therapies, announced today it has received an additional U.S. patent for its novel Delcath system, used to deliver high doses of chemotherapy to specific organs and body regions.
The patent expands the scope of the Delcath system to include use in treating glands with cancerous tumors, an extension of the therapy beyond organs and body regions previously patented by the Company. Delcath’s intellectual property portfolio now consists of 12 patents worldwide including the recently issued Canadian patent.
M.S. Koly, Delcath’s Chief Executive Officer, stated, “We are pleased Delcath has been issued this latest U.S. patent for its unique chemotherapy delivery system. We are confident the Delcath system can improve therapy for particular glands including the adrenals, prostate, thyroid and parathyroid gland.”
Unlike customary treatments of chemotherapy, the Delcath system delivers concentrated doses to the portion of the body harboring a cancer, leaving the rest of the body free from the affects of chemotherapy. This allows higher doses of these highly toxic chemotherapy drugs to be given without killing the patient.
“Delcath continues to build a strong platform for future growth. Our advanced technology has the ability to address a number of key markets as we continue our current trials and move toward beginning our fast-track Phase III clinical trials for the treatment of liver cancer using melphalan,” Koly added.
About Delcath
Delcath Systems is a developer of isolated perfusion technology for organ or region-specific delivery of therapeutic agents. The Company’s intellectual property portfolio currently consists of 12 patents on a worldwide basis, including the United States, Europe, Asia and Canada.
In May 2005, Delcath received fast-track status from the U.S. FDA for the treatment of metastatic melanoma in the liver with melphalan, an approved anticancer agent, using the Delcath system. For more information, please visit the Company’s website, http://www.delcath.com.
This release contains “forward-looking statements” based on current expectations but involving known and unknown risks and uncertainties. Actual results or achievements may be materially different from those expressed or implied. Delcath plans and objectives are based on assumptions involving judgments with respect to future economic, competitive and market conditions, its ability to consummate, and the timing of, acquisitions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond its control. Therefore, there can be no assurance than any forward-looking statement will prove to be accurate.
Delcath Systems, Inc.
CONTACT: M. S. Koly, Chief Executive Officer of Delcath Systems, Inc.,+1-203-323-8668; or Todd Fromer, +1-212-896-1215, tfromer@kcsa.com, orLewis Goldberg, +1-212-896-1216, lgoldberg@kcsa.com, both of KCSA Worldwidefor Delcath Systems, Inc.
Web site: http://www.delcath.com/
